NuCana (NCNA) Stock Price, News & Analysis

Company Overview

NuCana plc, headquartered in Edinburgh, Scotland, is a clinical-stage biopharmaceutical company focused on developing novel anti-cancer therapies. The company leverages its proprietary ProTide platform to deliver enhanced nucleoside analogues designed to overcome resistance mechanisms commonly encountered in standard chemotherapy regimens. NuCana’s research and development efforts are aimed at improving safety and efficacy profiles for patients with a range of solid tumor indications.

At the core of NuCana’s pipeline is NUC-3373, a next-generation fluoropyrimidine analogue engineered to bypass degradation pathways and achieve more consistent intracellular exposure. NUC-3373 is being evaluated in multiple Phase 2 studies, including trials in colorectal and gastric cancers. In addition to NUC-3373, the company is advancing NUC-7738, an innate immune response modulator, through early-stage clinical development. These programs exemplify NuCana’s strategy of applying its ProTide chemistry to diversify treatment options for oncology patients.

Founded in 2013, NuCana has grown from a UK-based research startup into a globally oriented organization with clinical operations and collaborations across North America and Europe. Under the leadership of Chief Executive Officer Alastair Smith, the company continues to expand its clinical footprint, engaging with academic institutions and industry partners to accelerate the development and potential commercialization of its drug candidates. NuCana remains committed to translating its proprietary chemistry platform into differentiated therapies that address unmet medical needs in cancer care.

Key Stats

• Today's Range: $3.81 to $4.15
• 50-Day Range: $2.86 to $11.92
• 52-Week Range: $2.78 to $732.00
• Volume: 227,723 shs
• Average Volume: 524,951 shs
• Market Capitalization: $116.70 thousand
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

NuCana Stock Analysis - MarketRank™

NuCana scored higher than 16% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for NuCana.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for NuCana are expected to grow in the coming year, from ($13.42) to ($10.52) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of NuCana is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of NuCana is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

NuCana has a P/B Ratio of 0.01. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

19.90% of the float of NuCana has been sold short.

Short Interest Ratio / Days to Cover

NuCana has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in NuCana has recently decreased by 2.45%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

NuCana does not currently pay a dividend.

Dividend Growth

NuCana does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

19.90% of the float of NuCana has been sold short.

Short Interest Ratio / Days to Cover

NuCana has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in NuCana has recently decreased by 2.45%, indicating that investor sentiment is improving.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

Search Interest

Only 11 people have searched for NCNA on MarketBeat in the last 30 days. This is a decrease of -58% compared to the previous 30 days.

MarketBeat Follows

Only 3 people have added NuCana to their MarketBeat watchlist in the last 30 days. This is a decrease of -90% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, NuCana insiders have not sold or bought any company stock.

Percentage Held by Insiders

31.20% of the stock of NuCana is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

44.00% of the stock of NuCana is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

NCNA Stock Analysis - Frequently Asked Questions

How have NCNA shares performed this year?

NuCana's stock was trading at $238.00 at the beginning of 2025. Since then, NCNA stock has decreased by 98.4% and is now trading at $3.86.

How were NuCana's earnings last quarter?

NuCana PLC Sponsored ADR (NASDAQ:NCNA) issued its earnings results on Wednesday, August, 20th. The company reported ($0.16) earnings per share for the quarter, topping the consensus estimate of ($2.75) by $2.59.

When did NuCana's stock split?

NuCana's stock reverse split on Friday, August 8th 2025.The 1-200 reverse split was announced on Friday, July 11th 2025. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, August 7th 2025. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split.

When did NuCana IPO?

NuCana (NCNA) raised $100 million in an initial public offering (IPO) on Thursday, September 28th 2017. The company issued 6,700,000 shares at $14.00-$16.00 per share. Citigroup, Jefferies and Cowen acted as the underwriters for the IPO and William Blair was co-manager.

How do I buy shares of NuCana?

Shares of NCNA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of NuCana own?

Based on aggregate information from My MarketBeat watchlists, some other companies that NuCana investors own include VBI Vaccines (VBIV), Anavex Life Sciences (AVXL), Sorrento Therapeutics (SRNE), Plug Power (PLUG), SCYNEXIS (SCYX), Allena Pharmaceuticals (ALNA) and CRISPR Therapeutics (CRSP).

Company Calendar

• Last Earnings: 8/20/2025
• Today: 9/23/2025
• Next Earnings (Estimated): 11/24/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:NCNA
• CIK: 1709626
• Web: www.nucana.com
• Phone: 441313571111
• Fax: N/A
• Employees: 30
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($646.16)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$24.28 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -592.28%
• Return on Assets: -208.68%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.58
• Quick Ratio: 1.58

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $267.86 per share
• Price / Book: 0.01

Miscellaneous

• Outstanding Shares: 30,000
• Free Float: 21,000
• Market Cap: $120.15 thousand
• Optionable: Not Optionable
• Beta: 1.39